 Home > Active Ingredient News > Antitumor Therapy > Clin Lung Cancer: The safety and efficacy of atezolizumab combined with ipilimumab in the treatment of treated advanced non-small cell lung cancer (NSCLC) with negative driver genes

Clin Lung Cancer: The safety and efficacy of atezolizumab combined with ipilimumab in the treatment of treated advanced non-small cell lung cancer (NSCLC) with negative driver genes

 Last Update: 2021-10-10
 Source: Internet
 Author: User

Tags

iron lung disease

immune cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

At present , the first-line standard treatment for advanced non-small cell lung cancer ( NSCLC ) with negative driver genes is immunotherapy monotherapy or combination chemotherapy
.

Immune checkpoint inhibitors (ICIs) include PD1 and PD-L1 inhibitors

At present , the first-line standard treatment for advanced non-small cell lung cancer ( NSCLC ) with negative driver genes is immunotherapy monotherapy or combination chemotherapy

The study included 23 patients, 3 patients (13.
0%) who had previously received combined immunotherapy (CPI)
.

The overall safety population for NSCLC includes 23 patients

The study included 23 patients, 3 patients (13.

A total of 204 adverse events (AEs) were reported in 22 patients (95.

Adverse events

In the overall population, 6 patients were confirmed as responders, with an ORR of 26.
1%
.

Five responders (25.

In the overall population, 6 patients were confirmed as responders, with an ORR of 26.

The median survival follow-up time of NSCLC patients who have not received CPI treatment in the past was 39.

Curative effect

The median survival follow-up of NSCLC patients who received CPI treatment was 39.
0 months (3.
3-39.
0 months); 3 patients (100%) had PFS events, and 2 patients (66.
7%) died
.

The median progression-free survival was 2.

The median survival follow-up of NSCLC patients who received CPI treatment was 39.

In summary, studies have shown that Atezolizumab combined with ipilimumab has shown certain efficacy in the treatment of treated advanced non-small cell lung cancer with negative driver genes, and the toxicity is controllable

Original source:

Wong DJ, Bauer TM, Gordon MS, et al.

Wong DJ, Bauer TM, Gordon MS, et al.
Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Results From a Phase 1b Trial.
Clin Lung Cancer.
2021 Jul 20:S1525-7304 (21)00183-2.
doi: 10.
1016/j.
cllc.
2021.
07.
002.
Epub ahead of print.
PMID: 34456145.
Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.